The May 2025 recall features four previously posted episodes on myasthenia gravis. The first episode has Dr. Fredrik Piehl discussing rituximab for new-onset generalized MG. In the second episode, Dr. Vera Bril explores the potential use of immunoglobulin as a corticosteroid-sparing agent in MG patients. The third episode features Dr. Ali A. Habib discussing trends in hospital admissions and in-hospital mortality for adult MG patients. The series concludes with Dr. Jennifer Morganroth addressing the increase in thymectomy procedures post-MGTX trial, disparities in access to these surgeries among different demographic groups, and the rise of minimally invasive surgical techniques.

Podcast links:

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

Hospitalizations and Mortality from MG Hospitalizations and Mortality From Myasthenia Gravis

Trends and Disparities in the Utilization of Thymectomy for MG in the US

Article links:

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

Hospitalizations and Mortality From Myasthenia Gravis

Trends and Disparities in the Utilization of Thymectomy for Myasthenia Gravis in the United States

Disclosures can be found at Neurology.org.